Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 110 Next >>

Filter Applied: gadolinium (Click to remove)

JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009

Inflammatory Progressive Multifocal Leukoencephalopathy in Human Immunodeficiency Virus-Negative Patients
Ann Neurol 62:34-39, Huang,D.R.,et al, 2007

Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006

Initial and Follow-up MR Imaging Findings in AIDS-Related Progressive Multifocal Leukoencephalopathy Treated with Highly Active Antiretroviral Therapy
AJNR 22:977-984, Thurnher,M.M.,et al, 2001

Unusual MRI & Pathologic Findings of PML Complicating Adult Wiskott-Aldrich Syndrome
Neurol 48:279-282, Matsushima,T.,et al, 1997

Neuroimaging Findings in Patients with AIDS
Clin Inf Dis 22:906-919, Walot,I.,et al, 1996

Progressive Multifocal Leukoencephalopathy:Unusual MR Findings
J Comput Assist Tomogr 19:302-305, Ng,S.,et al, 1995

Progressive Multifocal Leukoencephalopathy in 47 HIV-Sero (+) Pts:Neuroimaging, Clin, Path Correl
Radiolgoy 187:233-240, Whiteman,M.L.H.,et al, 1993

Progressive Multifocal Leukoencephalopathy:Contrast Enhancement on CT Scans and MR Images
AJR 161:1049-1051, Wheeler,A.L.,et al, 1993

Comparison of Triple Dose vs Std Dose Gadolinium-DTPA for Detect of MRI Enhanc Lesions in Pts with Primary Progr MS
JNNP 59:540-544, Filippi,M.,et al, 1995

Intramedullary Spinal Sarcoidosis:Clinical and Magnetic Resonance Imaging Characteristics
Neurol 43:333-337, Junger,s.S.,et al, 1993

Myelopathic Neurosarcoidosis:Diagnostic Value of Enhanced MRI
Neurol 41:150-151, Sauter,M.K.,et al, 1991

Deep Brain Nuclei T1 Shortening after Gadobenate Dimeglumine in Children: Influence of Radiation and Chemotherapy
AJNR 39:24-30, Kinner, S.,et al, 2018

Primary Angiitis of the Central Nervous System
Stroke 48:1248-1255, Boulouis, G.,et al, 2017

Clinicopathologic Conference, Diffuse Large B-Cell Lymphoma Consistent with Neurolymphomatosis
NEJM 376:2471-2481, Case 19-2017, 2017

Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017

Clippers with Diffuse White Matter and Longitudinally Extensive Spinal Cord Involvement
Neurol 86:103-105, Zhang, Y.X.,et al, 2016

Investigation of Leptomeningeal Enhancement in MS
Neurol 84:770-775, Eisele, P.,et al, 2015

IgG4-Related Disease and Hypertrophic Pachymeningitis
Medicine 92:206-216, Wallace, Z.,et al, 2013

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
Neurol 76:1858-1865, OConnor, P.W.,et al, 2011

Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010

Ring and Nodular Multiple Sclerosis Lesions: A Retrospective Natural History Study
Neurol 74:851-858, Davis,M.,et al, 2010

MRI Criteria for MS in Patients with Clinically Isolated Syndromes
Neurol 74:427-434, Montalban,X.,et al, 2010

Compressive Myelopathy Mimicking Transverse Myelitis
Neurologist 16:120-122, Kelley, B.,et al, 2010

Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study
Neurol 72:73-79, OConnor,P.,et al, 2009

Early MRI in Optic Neuritis: The Risk for Disability
Neurol 72:542-550, Swanton,.K.,et al, 2009

Clinicopath Conf, Neurosarcoidosis
NEJM 360:802-809, Case 6-2009, 2009

B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008

Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008

Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study
Lancet 372:1463-1472, Kappos,L.,et al, 2008

Bal�s Disease Showing Benign Clinical Course and Co-Existence with Multiple Sclerosis-Like Lesions in Chinese
Multiple Sclerosis 14:418-424, Wang,C.,et al, 2008

Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007

Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007

Standardized MR Imaging Protocol for Multiple Sclerosis:Consortium of MS Centers Consensus Guidelines
AJNR 27:455-461, Simon,J.H.,et al, 2006

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006

Clinicopath Conf., MELAS Syndrome
NEJM 353:2271-2280, Case 36-2005, 2005

Clinical and Magnetic Resonance Imaging Manifestations of Neurosarcoidosis
Semin Arthritis Rheum 34:649-661, Spencer,T.W.,et al, 2005

The MRI Appearance of Tumefactive Demyelinating Lesions
AJR 182:195-199, Given II,C.A.,et al, 2004

Oral Simvastin Treatment in Relapsing-Remitting Multiple Sclerosis
Lancet 363:1607-1608,1570, Vollmer,T.,et al, 2004

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 348:14-23, Miller,D.H.,et al, 2003

Clinicopath Conf., Chronic Inflammatory Demyelinating Polyneuropathy
NEJM 348:735-743, Case 6-2003, 2003

New T2 Lesions Enable an Earlier Diagnosis of Multiple Sclerosis in Clinically Isolated Syndromes
Ann Neurol 53:673-676, Dalton,C.M.,et al, 2003

Three Subsequent Single Doses of Gadolinum Chelate for Brain MR Imaging in Multiple Sclerosis
AJNR 24:658-662, Sardanelli,F.,et al, 2003

Peripheral Third Cranial Nerve Enhancement in Multiple Sclerosis
AJNR 24:1390-1395, Bhatti,M.T.,et al, 2003

The Utility of MRI in Suspected MS, Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 61:602-611,596, Frohman,E.M.,et al, 2003

MRI Predictors of Early Conversion to Clinically Definite MS in the CHAMPS Placebo Group
Neurol 59:998-1005, CHAMPS Study Group, 2002

Multiple Sclerosis and Magnetic Resonance Imaging
Arch Neurol 58:35-36, Racke,M.K.,et al, 2001

Assessing the Risk of Early Multiple Sclerosis in Patients with Clinically Isolated Syndromes: the Role of a Follow Up MRI
JNNP 70:390-393, Brex,P.A.,et al, 2001



Showing articles 0 to 50 of 110 Next >>